Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has completed the acquisition of 85.1% stake in Russia-based JSC Biosintez. All necessary formalities for the closure of transaction have been concluded and the process of the acquisition has been completed on December 20, 2016. This acquisition is consistent with Sun Pharma's philosophy to invest in strategic emerging markets. This transaction gives the company access to local manufacturing capability across multiple dosage forms in Russia, enabling us to serve the Russia pharmaceutical market more effectively. Earlier, in November, the company’s wholly owned subsidiary entered into definitive agreements for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical firm, engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.